PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report - A new report by visiongain, a London-based business information company, predicts that global revenues for biosimilars will reach $1.6 billion in 2012
World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/04/10 - A new report by visiongain, a London-based business information company, predicts that global revenues for biosimilars will reach $1.6 billion in 2012.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Visiongain forecasts that monoclonal antibodies will become the largest sector of the biosimilars market by 2022. Biosimilar monoclonal antibodies will reach developed markets, such as the US and the EU, by the middle of the decade, with Roche’s Rituxan likely to be the first target. By 2016, revenues for the segment will reach $849m. By then, however, biosimilar insulin and insulin analogues will be the largest sector of the market, having grown since 2011 with a CAGR of 41.4%.

Richard Lang, a pharmaceutical industry analyst at visiongain, said: “Biosimilars are an exciting opportunity for companies seeking to enter or maintain a presence in the biopharmaceutical industry. Sandoz and Teva are the major players in developed markets currently, although their position will be challenged in the near future by many other generics and Big Pharma companies. Merck & Co.’s potential $720m deal with Hanwha Chemical shows the level of money companies are willing to invest in this fast-growing market.”

This study forecasts revenues of six leading segments of the biosimilar market. In 2011, erythropoietins, G-CSF and growth hormones accounted for 42.1%. Products from these sectors are available in most major developed and emerging markets, although uptake is varied for each class. Sandoz’ Omnitrope (somatropin), for example, accounts for less than 5% of the US growth hormones market.

The new report also discusses leading national markets for biosimilars. In 2011, China was the largest national market, although with around 150 players, the market there is fragmented. The US market will remain small in 2012, as patents continue to cover many leading biologics. However, the release of draft development guidelines by the FDA in February 2012, as well as patent expiries from 2014 onwards, will cause strong growth towards the middle of the decade. By 2022, the US will be the world’s second largest market for biosimilars.

Rising incidence of diseases, cost restrictions by healthcare payers and biologic patent expiries will all act as growth drivers for this rapidly expanding industry and market. Increasing interest from leading pharmaceutical companies, multinational generics manufacturers and biotechnology companies will give strong growth for the world biosimilar market from 2012 onwards. Biosimilars and Follow-On Biologics: World Market 2012-2022 adds to visiongain’s range of analytical research reports on the biopharmaceutical industry.

For sample pages and further information concerning the visiongain report the Biosimilars and Follow-On Biologics: World Market 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Rapid Recovery

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)